CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published in July, Professor Jerry Radich has selected topical, interesting papers for your perusal. Papers with a clinical, scientific, pediatric and low and middle income country focus are shared.
July 2026
Clinical CML papers
Introduction to the review series. Chronic myeloid leukemia in 2026
Radich J. Haematologica, July 2026
open access publication
Favorable tolerability of Asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia
Issa GC et al. Haematologica, July 2026 (epub ahead of print)
open access publication
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results
Cortes JE et al. Leukemia, July 2026 (epub ahead of print)
open access publication
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
Kantarjian H et al. Leukemia, July 2026 (epub ahead of print)
open access publication
Diabetic patients with newly diagnosed chronic myeloid leukemia: TKI choice and early adverse events. A real-life survey with the Italian CML Network
Russo S et al. Eur J Haematol, July 2026 (epub ahead of print)
Development and external validation of a transcriptome-based multivariable prediction model for treatment-free remission in chronic myeloid leukemia
Alcazer V et al. J Clin Oncol, July 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic-phase: Results of the Japan Adult Leukemia Study Group RE-STOP219 Study
Iriyama N et al. Br J Haematol, July 2026 (epub ahead of print)
open access publication
Olverembatinib: real progress in BCR::ABL1 leukemia?
Oehler VG et al. Haematologica, July 2026 (epub ahead of print)
open access publication
Frontline nilotinib versus dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on Agenzia Italiana del Formaco Monitoring Registries
Breccia M et al. Clin Lymphoma Myeloma Leuk, July 2026
Ponatinib safety profile: An analysis of 10 years of real-world experience
Jabbour E et al. Drug Saf, July 2026 (epub ahead of print)
open access publication
Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukemia
Fujita M and Ureshino H. Br J Haematol, July 2026
Real-world evidence-based study on treatment-free remission in chronic myeloid leukemia
Cheng F et al. J Natl. Compr Canc Netw, July 2026 (epub ahead of print)
open access publication
Scientific CML papers
Improved inter-lab precision after CML international scale adaptation: a 15-year history of BCR::ABL1 proficiency testing
Kim AS et al. Leukemia, July 2026 (epub ahead of print)
open access publication
Development and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts
Damerchiloo F et al. Sci Rep, July 2026 (epub ahead of print)
open access publication
Measurable residual disease and the unresolved biology of leukemic stem cells
Bhartiya D et al. Stem Cell Rev Rep, July 2026 (epub ahead of print)
Genetic Profile, Treatment Response, and Outcomes of BCR::ABL1-Positive Mixed-Phenotype Acute Leukemia: A Study From the BCR::ABL1 Pathology Group
Shen Q., et al. Modern Pathology, May 2026
open access publication
Pediatric CML papers
Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukemia: Towards practical implementation and interpretation of measured plasma concentrations
Lensker P et al. Clin Pharmacokinet, July 2026 – open access publication
Treatment patterns and outcomes of pediatric chronic myeloid leukemia in a Brazilian multicentre cohort
da Silva MEM et al. Pediatr Blood Cancer, July 2026 (epub ahead of print)
LMIC CML papers
Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review
Özmen D et al. Leuk Res, July 2026
BCR-ABL1 transcript variants in chronic myeloid leukemia patients in Africa: A systematic review
Emeline Oloume M et al. Health Sci Rep, July 2026
open access publication
Study on efficacy and safety of dasatinib 50 mg in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP): Experience from a tertiary care hospital
Banarjee A et al. Indian J Hematol Blood Transfus, July 2026
Optimizing treatment-free remission (TFR) in chronic myeloid leukemia: Challenges and a modified monitoring strategy – real-world data from Eastern India
Parihar M et al. Indian J Haematol Blood Transfus, July 2026
Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population
Sharif F et al. Hematol Transfus Cell Ther, July 2026 (epub ahead of print)
open access publication